The USC Norris Comprehensive Cancer Center utilizes a well-established system for Planning and Evaluation that engages institutional leaders, Senior Leaders, Program Leaders, Shared Resources Directors, Cancer Center members and staff, advisors, and patient advocates. This effort includes well-tested and integrated mechanisms to monitor, evaluate, and adjust the Center?s Research Program activities, Shared Resource services, funding allocations, and strategic directions to ensure alignment with the Center?s vision and goals. Planning and Evaluation ensures that future directions are achievable and that resources and investments are targeted effectively, while providing the ability to respond to new opportunities and changes in the field. Our Planning and Evaluation process also is highly integrated with institutional planning and resource allocation activities to assure alignment and ability to capitalize on institutional investments. USC Norris employs a variety of Planning and Evaluation activities, supported in part by the CCSG funds. These include: External Advisory Board and ad hoc reviewers; Center-wide and Research Program retreats; Leadership Retreats; formal strategic planning; bi-weekly Executive Committee and Director?s Cabinet meetings; and monthly Leadership Council meetings. Under Dr. Gruber, strategic and programmatic planning and evaluation processes have been transformed and have become embedded in our culture. We have instituted a multi-year strategic plan that guides leadership decisions and investments. Leadership has been increasingly effective in defining and realizing the Cancer Center?s vision, using planning and evaluation mechanisms to guide decisions, assess progress, and make changes to assure success. In addition, the Executive Committee now conducts intensive annual program and core reviews, through which they carefully assess progress against milestones, future relevance, leadership and future aims.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Career Development (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Los Angeles
United States
Zip Code
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472
Peddi, Santosh; Pan, Xiaoli; MacKay, John Andrew (2018) Intracellular Delivery of Rapamycin From FKBP Elastin-Like Polypeptides Is Consistent With Macropinocytosis. Front Pharmacol 9:1184
Guo, Hao; Lee, Changrim; Shah, Mihir et al. (2018) A novel elastin-like polypeptide drug carrier for cyclosporine A improves tear flow in a mouse model of Sjögren's syndrome. J Control Release 292:183-195
Zhao, Yi; Wu, Kaijin; Wu, Yongfeng et al. (2018) Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol 11:113-121
Kahn, Michael (2018) Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators. Prog Mol Biol Transl Sci 153:209-244
Park, Sungshim L; Patel, Yesha M; Loo, Lenora W M et al. (2018) Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations. Clin Epigenetics 10:110
Liu, Jie; Liang, Gangning; Siegmund, Kimberly D et al. (2018) Data integration by multi-tuning parameter elastic net regression. BMC Bioinformatics 19:369
McDonnell, Kevin J; Chemler, Joseph A; Bartels, Phillip L et al. (2018) A human MUTYH variant linking colonic polyposis to redox degradation of the [4Fe4S]2+ cluster. Nat Chem 10:873-880
Schirripa, Marta; Zhang, Wu; Yang, Dongyun et al. (2018) NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. PLoS One 13:e0193640

Showing the most recent 10 out of 842 publications